123 related articles for article (PubMed ID: 2942246)
1. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer.
Goss PE; Ashley S; Powles TJ; Coombes RC
Cancer Treat Rep; 1986 Jun; 70(6):777-9. PubMed ID: 2942246
[TBL] [Abstract][Full Text] [Related]
2. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
3. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
4. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
5. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.
Pannuti F; Martoni A; Lenaz GR; Piana E; Nanni P
Cancer Treat Rep; 1978 Apr; 62(4):499-504. PubMed ID: 350387
[TBL] [Abstract][Full Text] [Related]
6. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
7. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
8. [Clinical trial of high-dose medroxyprogesterone acetate in advanced breast cancer].
Jiang Z; Song S; Li J
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):71-3. PubMed ID: 7656795
[TBL] [Abstract][Full Text] [Related]
9. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
10. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
12. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study.
Tan YO; Hendrickson C; McWhirter K; Kohler M; Hannigan JF; Carlson RW
Cancer Treat Rep; 1987 Oct; 71(10):969-70. PubMed ID: 2958131
[No Abstract] [Full Text] [Related]
14. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
[No Abstract] [Full Text] [Related]
15. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
[TBL] [Abstract][Full Text] [Related]
16. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary results of treatment of hormone-dependent metastatic carcinoma of the breast with the bromocriptin-medroxyprogesterone acetate combination].
Mussa A; Dogliotti L; Di Carlo F
Minerva Med; 1977 Jun; 68(32):2233-44. PubMed ID: 577604
[TBL] [Abstract][Full Text] [Related]
19. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.
Hortobagyi GN; Buzdar AU; Frye D; Yap HY; Hug V; Pinnamaneni K; Fraschini G; Halvorson HC; Blumenschein GR
Breast Cancer Res Treat; 1985; 5(3):321-6. PubMed ID: 3161565
[TBL] [Abstract][Full Text] [Related]
20. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
